Phillips-Medisize Introduces Disposable Pen Injector
The injector is designed to be smaller but also offers customizable dosing and push-button colors to signal different dosing and drug requirements.
- By David Kopf
- Feb 09, 2023
Phillips-Medisize, a Molex company that makes drug delivery, diagnostic and MedTech devices, has released a disposable pen injector that pharmacies could soon be seeing.
The pen injector has been designed to match familiar disposable pen products with which users have experience but is noticeably smaller. It also features a flexible design with customizable dosing as well as push-button colors to signal different dosing and drug requirements for therapies such as diabetes, fertility, growth hormones, obesity and osteoporosis.
Suited for high-volume manufacturing, the pen injector aims to facilitate faster, more efficient and cost-effective market entry for pharmaceuticals.
“A Pen Injector is an important addition to Phillips-Medisize’s expanding product and platform portfolio that empowers Biopharma companies to accelerate the rollout of novel and generic drug treatments at significant economies of scale,” said Paul Chaffin, senior vice president and president of Medical and Pharmaceutical Solutions, Molex. “This ‘ready to go’ solution offers all of the advantages expected from ‘state of the art’ pen designs while benefiting from our decades of device development and large-volume manufacturing expertise to reduce the challenges of bringing affordable drugs and drug-delivery devices to market.”
Sample devices are available to support technical evaluation and human factors studies, with clinical devices scheduled for the end of 2023. That’s a key consideration for drug-delivery companies working to respond to the rapidly expanding billion-unit-plus disposable pen injector market.
About the Author
David Kopf is the Publisher HME Business, DME Pharmacy and Mobility Management magazines. He was Executive Editor of HME Business and DME Pharmacy from 2008 to 2023. Follow him on LinkedIn at linkedin.com/in/dkopf/ and on Twitter at @postacutenews.